Brought to you by 
ThromboGenics teams up with Eleven Biotherapeutics for back-of-the-eye disease treatment
25 Nov 2014
Executive Summary
Three-year-old protein-based therapeutics developer Eleven Biotherapeutics has agreed to use its AMP-Rx protein design technology to optimize one of ThromboGenics NV’s therapeutics. The biologic will be used to treat back-of-the-eye diseases, including diabetic macular edema.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ThromboGenics teams up with Eleven Biotherapeutics for back-of-the-eye disease treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice